XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUES - Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenues $ 7,042 $ 7,421 $ 19,892 $ 20,061
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,928 5,509 13,622 14,002
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,101 1,031 3,378 3,559
Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 1,013 881 2,891 2,500
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 6,978 7,356 19,650 19,848
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,900 5,479 13,482 13,932
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,064 997 3,281 3,419
Total product sales | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 1,013 880 2,887 2,497
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 4,487 4,189 12,422 11,777
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3,661 3,302 9,906 9,132
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 541 602 1,653 1,776
Total HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 285 285 863 869
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 2,766 2,276 7,472 6,094
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,286 1,875 6,088 4,926
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 278 254 807 707
Biktarvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 201 147 577 461
Complera/Eviplera        
Disaggregation of Revenue [Line Items]        
Total revenues 43 64 142 189
Complera/Eviplera | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 20 28 56 73
Complera/Eviplera | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 21 31 76 104
Complera/Eviplera | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 5 10 12
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 500 433 1,335 1,227
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 444 355 1,152 994
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 28 42 92 128
Descovy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 28 36 91 105
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 600 744 1,764 2,123
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 502 576 1,441 1,633
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 71 100 220 306
Genvoya | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 27 68 103 184
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 374 399 1,077 1,148
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 276 275 763 773
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 86 112 278 336
Odefsey | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 12 12 36 39
Stribild        
Disaggregation of Revenue [Line Items]        
Total revenues 32 42 98 139
Stribild | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 22 28 68 94
Stribild | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 11 23 33
Stribild | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 7 12
Truvada        
Disaggregation of Revenue [Line Items]        
Total revenues 30 67 102 310
Truvada | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 24 55 77 268
Truvada | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 3 5 12 18
Truvada | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 2 7 13 24
Revenue share - Symtuza        
Disaggregation of Revenue [Line Items]        
Total revenues 130 130 388 394
Revenue share - Symtuza | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 85 86 251 261
Revenue share - Symtuza | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 40 41 126 125
Revenue share - Symtuza | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 3 10 8
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 12 34 45 153
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 1 24 11 110
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 6 6 20 19
Other HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 5 4 15 24
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 925 1,923 2,905 4,208
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 336 1,527 1,179 2,763
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 130 109 560 761
Veklury | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 458 287 1,166 684
Total HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 524 429 1,371 1,488
Total HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 283 224 745 809
Total HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 143 94 332 322
Total HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 98 111 294 357
Ledipasvir/Sofosbuvir        
Disaggregation of Revenue [Line Items]        
Total revenues 25 45 83 163
Ledipasvir/Sofosbuvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 8 14 27 63
Ledipasvir/Sofosbuvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 5 13 24
Ledipasvir/Sofosbuvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 12 26 43 76
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 455 332 1,161 1,155
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 241 173 629 649
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 131 77 288 234
Sofosbuvir/Velpatasvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 84 82 244 272
Other HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 44 52 127 170
Other HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 34 37 88 97
Other HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 12 31 64
Other HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 2 3 7 9
Total HBV/HDV        
Disaggregation of Revenue [Line Items]        
Total revenues 264 247 733 704
Total HBV/HDV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 131 104 311 275
Total HBV/HDV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 28 29 85 76
Total HBV/HDV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 106 114 337 353
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 228 208 622 589
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 129 103 306 266
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 9 27 25
Vemlidy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 90 96 289 298
Viread        
Disaggregation of Revenue [Line Items]        
Total revenues 22 26 69 85
Viread | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2 1 4 8
Viread | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 7 17 22
Viread | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 15 18 48 55
Other HBV/HBD        
Disaggregation of Revenue [Line Items]        
Total revenues 14 13 42 30
Other HBV/HBD | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 1 1
Other HBV/HBD | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 13 13 41 29
Other HBV/HBD | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Total cell therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 398 222 1,040 632
Total cell therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 270 135 688 394
Total cell therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 111 78 308 213
Total cell therapy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 17 9 44 25
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 81 47 217 119
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 60 35 160 94
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 20 12 56 25
Tecartus | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 1 0 2 0
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 317 175 823 513
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 210 100 528 300
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 91 66 253 188
Yescarta | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 16 9 42 25
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 180 101 485 262
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 139 100 379 261
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 38 1 98 1
Trodelvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 0 8 0
Total other        
Disaggregation of Revenue [Line Items]        
Total revenues 200 245 693 777
Total other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 80 87 275 298
Total other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 75 84 244 270
Total other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 46 74 174 209
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 105 143 380 420
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 9 7 48 32
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 63 67 192 202
AmBisome | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 33 69 140 186
Letairis        
Disaggregation of Revenue [Line Items]        
Total revenues 43 46 135 157
Letairis | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 43 46 135 157
Letairis | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Letairis | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 52 56 178 200
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 34 91 109
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 11 17 52 68
Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 13 5 35 23
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 64 65 242 213
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 30 140 70
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 37 34 98 140
Royalty, contract and other revenues | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues $ 0 $ 1 $ 4 $ 3